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Introduction: Lung cancer is the leading cause of cancer-related death in Europe and the US. Isolated metastases
to skeletal muscle and the mandible are very uncommon.
Case presentation: This report presents two cases. Case 1 concerns a 45-year-old Caucasian woman affected by
muscle metastasis of the right thigh from non-small-cell lung cancer. Case 2 concerns a 61-year-old Caucasian man
affected by mandible metastasis from non-small-cell lung cancer. Both metastases were detected by diagnostic
imaging studies. Both patients were treated with radiation therapy with palliative and antalgic intent.
Conclusion: Radiation therapy was effective and well tolerated in both cases. Both our patients are alive, with
follow-up of 18 months and five months, respectively.
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Lung cancer is the leading cause of cancer-related death
worldwide and the second most common cancer in both
men and women. Despite improvements in imaging tech-
nologies over the past two decades, the majority of lung
cancers are discovered because of the development of dis-
tant metastases. Hematogenous spread with multiple
organ involvement is frequently reported. Commonly, me-
tastases from lung cancer involve the liver, adrenal glands,
bone and brain [1]. Muscle metastases are uncommon [2].
Mandible metastasis from lung cancer is a rare condition
that may occur in the late stages of the disease [3]. We de-
scribe two cases of non-small-cell lung cancer (NSCLC)
metastasis to thigh muscle and mandible bone (as first
clinical evidence), and discuss treatments and outcomes.
Case presentation
Case 1
A 45-year-old Caucasian woman presented to our facility
with a history of right shoulder pain that had persisted
for several months and was resistant to medical treat-
ments. She reported no systemic disease. She had been a* Correspondence: francesca_giugliano@hotmail.com
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reproduction in any medium, provided the orsmoker for 25 years. A contrast-enhanced computed
tomography (CT) scan of the chest revealed a right
upper lobe lung mass (64×47mm) and mediastinal
lymphadenopathy that did not involve the chest wall.
CT-guided biopsy of the lung mass provided a histo-
pathological diagnosis of adenocarcinoma (staining for
thyroid transcription factor 1 (TTF-1) was positive,
staining for p63 was negative). On further staging, brain
metastasis was detected (33mm in left parietal region). A
whole body 18F-fluorodeoxyglucose (FDG) positron
emission tomography (PET) scan was performed and it
revealed increased FDG uptake in the primary right
upper lobe lung mass, mediastinum and brain (standard-
ized uptake values (SUVs) of 11.5, 6.1 and 13.3, respect-
ively). She underwent neurosurgery and the histological
report described the brain lesion as compatible with origin
from the primary lung tumor. She received six cycles of
systemic chemotherapy consisting of cisplatin and
pemetrexed. At one-month follow-up, a PET/CT (Figure 1)
scan showed stable FDG uptake in body regions of inter-
est. She received 45Gy (2.5Gy×25 fractions) sequential pal-
liative radiation therapy (RT) on the lung mass, and 30Gy
(3Gy×10 fractions) on whole brain, respectively. Figure 1
shows an axial section of the treatment planning CT scan
fused with the PET scan. Three months after RT, a
CT scan revealed stable lung and brain disease. She wasral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 An axial section of the treatment planning computed tomography scan fused with positron emission tomography. A right
upper lobe lung mass can be seen.
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chloride plus ARQ-197 (a selective inhibitor of the c-Met
receptor tyrosine kinase)/placebo [4]. One month later,
she came to our Radiation Therapy Department for
follow-up, and she referred to ha skin lesion first noticed
on her right thigh two weeks previously. A physical exam-
ination showed phlebitis and edema of the lower limb. For
this reason we prescribed low-molecular-weight heparin.
Despite multimodality therapy, a new CT total body scan
pointed out progressive metastatic disease with a rare le-
sion of the soft tissue in the medial compartment of the
right thigh, infiltrating the skin (Figure 2). UltrasonographyFigure 2 An axial section of a computed tomography scan showing a
right thigh.(USG) was performed to evaluate the thigh lesion; it
showed an inhomogeneous, hypoechoic image, with ir-
regular margins (50×40mm). This lesion enveloped con-
tiguous superficial vessels, involved the subcutaneous
tissue and infiltrated the skin. Fine needle aspiration cy-
tology (FNAC) was performed. After cytological definition
as a muscle metastasis consistent with the known primary
lung cancer, she was treated with RT to the right thigh
mass with 30Gy in 10 fractions. She developed pain in her
left hemithorax and a single photon emission computed
tomography (SPECT) study showed increased uptake in
the area of the ninth rib. A single fraction of RT waslesion in the soft tissue of the medial compartment of the
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treatments. She is alive 18 months on from diagnosis, with
metastatic disease; she has no symptoms related to the
metastasis and only an ulcerated lesion is visible on her
right thigh. The last USG showed a reduction of the lesion
(19×7mm). The radiation treatments made reducing the
dose of analgesic therapy possible, and resulted in reso-
lution of edema of her leg. RT has improved the quality of
life of our patient. Our patient is currently undergoing
therapy with gemcitabine.
Case 2
A 61-year-old Caucasian man came to our Radiation
Oncology Department with a palpable mass of the man-
dible on the left side. Our patient reported that he had
noted the mandible lesion about two months earlier,
with atypical pain. This pain had worsened acutely in
the 24 hours before the clinical examination, until it be-
came unbearable. He had been a smoker for more than
30 years. He was apparently in good health otherwise.
He reported that he had no systemic disease. A physical
examination showed a significant swelling of the left
mandible; as our patient had given no history of trauma,A
B
C
Figure 3 Radiation treatment planning: (A) ninth rib, (B) right upper l
three-dimensional reconstructions.the cause of his signs and symptoms was presumed to
be related to either infection or malignancy. During the
investigation of the pain, a total body CT scan showed a
bone lesion of the left mandible (17mm) plus a left lung
mass (size at maximum of 37mm), with involvement of
the mediastinum. A bone biopsy was performed, show-
ing a metastasis from an epidermoid carcinoma grade 2,
consistent with the primary lung cancer. A PET/CT scan
identified increased FDG uptake (Figure 4) in the man-
dible bone (SUV maximum of 6.3) and left lung mass
(SUV maximum of 3.2). Our patient’s case was discussed
at our multidisciplinary committee: the surgeon’s thera-
peutic proposal was a double concomitant surgery on
the lung mass and on the solitary bone metastasis; the
radiotherapist and oncologist recommended radiation
therapy on the bone metastasis followed by systemic
therapy. Our patient refused the surgical option as wors-
ening his quality of life. He received symptomatic and
palliative RT (Figure 5) on the left mandible bone lesion
with 8Gy in a single fraction, allowing the initiation of
chemotherapy. Three months after the completion of
radiation treatment he is alive but he has reported a
slight increase in pain on the mandible site, refractory toA1
B1
C1
obe lung mass, (C) right thigh lesion; (A1), (B1) and (C1) show
Figure 4 A positron emission tomography/computed
tomography scan identified increased fluorodeoxyglucose
uptake in the mandible bone.
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pain, we will propose retreatment on the mandible site [5].
Conclusions
This report presents the cases of two patients affected
by NSCLC, metastatic to the right thigh muscle and left
mandible. Both patients were treated with RT to the in-
volved area, in addition to systemic chemotherapy. Few
data are reported about metastases to muscle from pri-
mary lung cancer. Moreover, metastases to soft tissue
can be misdiagnosed histologically as primary soft tissue
sarcomas. The treatment and prognosis for a metastaticFigure 5 Radiation treatment planning in a single fraction of mandibneoplasm of the soft tissue and a primary soft tissue sar-
coma are different [6]. Various mechanical factors, such
as tissue blood flow, arterial pressure, muscle contrac-
tion and trauma, have been described as possible causes
for rare metastases to muscle [7]. Often these metastases
are diagnosed at different time intervals from the discov-
ery of the primary tumor, being discovered in some cases
more than five years later. The most commonly involved
sites are the muscles of the trunk, particularly the
paraspinal and psoas muscles [8]. In our first patient’s
case, however, the region of interest was the lower ex-
tremity. Many cases of skeletal muscle metastases de-
scribed in the literature showed clinical symptoms and
signs, such as in our patient with edema and phlebitis. Al-
though several reports underline that these events are not
common, a recent study by Haygood et al. explores the
epidemiology of metastases to skeletal muscle and their
detection by PET/CT, concluding that skeletal muscle me-
tastases are not unusual and the most common source is
lung cancer [9]. The increasing use of PET/CT has re-
cently led to diagnosis of unsuspected distant/solitary
metastases at rare locations, including the colon and
extra-ocular muscles [10]. There is no agreement on the
optimal therapeutic strategy for muscle metastases from
NSCLC, although several therapeutic options can be of-
fered to patients such as radiation therapy, chemotherapy
or surgical excision. Unfortunately, the outcome remains
poor and the prognosis of these patients with muscle me-
tastasis from NSCLC remains doubtful [11]. In this report,
with regard to our first patient, the use of radiation ther-
apy on muscle metastasis can be considered as a po-
tentially successful treatment option, giving patients the
possibility to avoid an aggressive treatment such as surgery
and reducing the possible side effects.
Likewise, the clinical presentation of mandibular metas-
tases are similar to common conditions such as toothache
or, less frequently, temporo-mandibular joint pain, osteo-
myelitis, or trigeminal neuralgia [12]. Consequently the
diagnostic and therapeutic investigation of these patients
may be difficult. Metastases to the jaw involve the man-
dible in 80 percent of cases, and the most commonle bone (left); three-dimensional reconstruction (right).
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regions of the mandibular bone. Most studies of oral
metastatic disease indicate its predilection for the poster-
ior mandible [12,13] because of its rich blood supply in ac-
tive areas of hematopoiesis; conversely, in our study, the
anterior of the mandible was involved. Metastatic bone le-
sions are generally determined after the detection of the
primary tumor; they may be the first symptom of meta-
static disease in approximately 30 percent of cases. Data
from the literature reveal that autopsies detected muscle
metastases in about 17 percent of patients [14]. In the sec-
ond case report, we described the clinical history of a pa-
tient affected by metastasis to the mandible that disclosed
the presence of a silent primary lung cancer. Pruckmayer
et al. evaluated 763 patients retrospectively who suffered
from jaw pain. They concluded that a selected subgroup
of individuals, specifically patients with a history of cancer
or those not responding to conventional management,
should undergo specific investigations such as bone scans
to rule out a neoplastic cause [15].
Although radical surgery treatment of the solitary
metastatic bone lesion or of muscle metastasis in pa-
tients who are oligometastatic and plurimetastatic could
be considered as therapeutic options, palliative radiation
therapy was offered to our patients obtaining good con-
trol of tumor size and pain. Both patients are alive, with
follow-up of five and 18 months. Palliative radiation
therapy is one of the major contributors to the care of
patients with oncological issues, and also, in selected
cases, a second radiation therapy treatment is feasible,
well tolerated and offers the possibility of symptomatic
relief. Our treatments were carefully chosen to maintain
the quality of life of our patients in both cases, and we
obtained good results without serious side effects al-
though it should be noted the prognosis in metastatic
NSCLC remains poor.Consent
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for review by the Editor-in-Chief of this journal.
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